Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.76 is in line with its 5-year average of -1.76, around the middle of its 5-year range (-3.53–-0.51).
23.77% above its 12-month average of -2.31.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.20.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 16 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.76
EARNINGS PER SHARE (EPS) AVG TTM
-2.31
EARNINGS PER SHARE (EPS) AVG 3Y
-2.36
EARNINGS PER SHARE (EPS) AVG 5Y
-1.76
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+23.77%
CURRENT VS 3Y AVG
+25.27%
CURRENT VS 5Y AVG
-0.06%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Oculis Holding AG
Market Cap
$494.52M
Earnings Per Share (EPS)
-1.76
TTM Avg
-2.31
3Y Avg
-2.36
5Y Avg
-1.76
Market Cap
$499.40M
Earnings Per Share (EPS)
1.08
TTM Avg
0.77
3Y Avg
0.47
5Y Avg
0.21
Market Cap
$503.93M
Earnings Per Share (EPS)
-0.67
TTM Avg
-1.09
3Y Avg
-1.67
5Y Avg
-1.68
Market Cap
$486.01M
Earnings Per Share (EPS)
-0.52
TTM Avg
-0.81
3Y Avg
-1.01
5Y Avg
-1.63
Market Cap
$504.04M
Earnings Per Share (EPS)
-7.58
TTM Avg
-39.00
3Y Avg
-56.28
5Y Avg
-76.67
Market Cap
$504.84M
Earnings Per Share (EPS)
-0.95
TTM Avg
-1.56
3Y Avg
-1.33
5Y Avg
-1.41
Market Cap
$502.81M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.57
3Y Avg
-1.57
5Y Avg
-1.57
Market Cap
$483.80M
Earnings Per Share (EPS)
0.52
TTM Avg
0.62
3Y Avg
0.43
5Y Avg
-0.09
Market Cap
$475.91M
Earnings Per Share (EPS)
-1.73
TTM Avg
-1.90
3Y Avg
-1.16
5Y Avg
-1.16
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oculis Holding AG (OCS) | $494.52M | -1.76 | -2.31 | -2.36 | -1.76 |
| Tactile Systems Technology, Inc. (TCMD)vs › | $499.40M | 1.08 | 0.77 | 0.47 | 0.21 |
| Allogene Therapeutics, Inc. (ALLO)vs › | $503.93M | -0.67 | -1.09 | -1.67 | -1.68 |
| Evolus, Inc. (EOLS)vs › | $486.01M | -0.52 | -0.81 | -1.01 | -1.63 |
| Crescent Biopharma, Inc. (CBIO)vs › | $504.04M | -7.58 | -39.00 | -56.28 | -76.67 |
| 908 Devices Inc. (MASS)vs › | $504.84M | -0.95 | -1.56 | -1.33 | -1.41 |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $502.81M | N/A | -1.57 | -1.57 | -1.57 |
| Puma Biotechnology, Inc. (PBYI)vs › | $483.80M | 0.52 | 0.62 | 0.43 | -0.09 |
| Contineum Therapeutics, Inc. (CTNM)vs › | $475.91M | -1.73 | -1.90 | -1.16 | -1.16 |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | -0.58 | -1.12 | -1.21 | -1.27 |
Trailing EPS (TTM)
$-1.76
Forward EPS (Est.)
N/A
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.28 |
| 2024-12-31 | -2.33 |
| 2023-12-31 | -3.53 |
| 2022-12-31 | -1.28 |
| 2021-12-31 | -0.62 |
| 2020-12-31 | -0.51 |
